Valuation of Medical Corporations: Appropriate Use of DCF, Net Asset, and Comparable Company Methods

📖 Approx. 9 minPublished: 2026.05.05 ／ Updated 2026.05.08

In M&A and business succession for medical corporations, determining a fair transfer price is extremely important. However, due to the unique assets and revenue structures of medical corporations, caution is necessary when applying general business valuation methods. This article, written by experts in medical corporation M&A, provides an easy-to-understand explanation of the characteristics of major valuation methods such as the DCF method, net asset method, and comparable company method, and how to use them appropriately, aimed at directors and presidents of medical institutions, those considering M&A, and professionals. Accurate business valuation is the first step towards a smooth M&A and the maintenance and development of future medical care provision systems.

Importance of Business Valuation in Medical Corporation M&A

In M&A and business succession for medical corporations, objective and rational business valuation is indispensable for both the seller and the buyer. For the seller, it serves as the basis for ensuring their medical institution’s long-term efforts and assets are fairly evaluated and that they receive an appropriate price. Particularly for medical corporations with equity stakes, the value of these stakes directly impacts the compensation for succession. For the buyer, it serves as a benchmark to verify the reasonableness of post-acquisition management plans and to determine if the investment will yield adequate returns or if future growth is expected. Business valuation also plays a crucial role in obtaining financing from financial institutions and in calculating capital gains for tax purposes.

For medical corporations, revenue is heavily dependent on the fixed prices of medical fees, and fixed assets such as medical equipment and real estate, as well as intangible assets like licenses and personnel, significantly influence value. Considering these characteristics, understanding multiple valuation methods and appropriately combining them according to the situation leads to a more precise business valuation.

Major Business Valuation Methods and Their Characteristics

The following three main methods are primarily used for valuing medical corporations. Each has its advantages and disadvantages, and the optimal method or combination varies depending on the scale of the medical corporation, its business content, and the purpose of succession.

1. DCF Method (Discounted Cash Flow)

The DCF method calculates business value by forecasting the free cash flow (FCF) generated from future business activities and discounting it to its present value. It is one of the most commonly used valuation methods in M&A practice and is effective when emphasizing the future potential and profitability of a business. For medical corporations, it is necessary to incorporate forecasts of future medical fee revisions, changes in demand based on regional medical care plans, trends in competing clinics, and the introduction of new medical technologies into the projections.

Advantages of the DCF Method:

• Can reflect the future potential and profitability of the business
• Easy to consider M&A synergy effects (e.g., efficiency gains from mergers/integrations)
• Can be utilized for strategic business planning

Disadvantages of the DCF Method:

• The accuracy of future cash flow forecasts significantly impacts the valuation
• Discount rate settings tend to be subjective
• Difficult to set the forecast period

The forecast period is typically set at around 5 to 10 years, but for medical corporations, it is necessary to devise methods for longer-term forecasts or terminal value calculations, considering the revision cycles of medical fees and the rapid pace of medical technological advancements. Additionally, while WACC (Weighted Average Cost of Capital) is often used for the discount rate, it is crucial to accurately reflect the risk characteristics of the medical corporation.

2. Net Asset Method

The net asset method values a company based on its net assets, calculated by subtracting liabilities from assets. It is characterized by valuation at fair market value rather than book value. It allows for relatively objective valuation and is sometimes used for asset-sale M&A, small clinics, or when the continuity of the business is in question. For medical corporations, the fair market valuation of real estate such as land and buildings, high-value medical equipment, and inventory such as pharmaceuticals is important.

Advantages of the Net Asset Method:

• Objective valuation is possible
• Valuation is relatively easy
• Serves as a benchmark for dissolution value (liquidation value)

Disadvantages of the Net Asset Method:

• Cannot reflect future profitability or growth potential
• Difficult to value intangible assets (brand power, know-how, licenses, etc.)
• Setting standards for fair market valuation can be difficult

For medical corporations, especially medical equipment and real estate, there can be significant discrepancies between book value and fair market value depending on the acquisition date and depreciation status. Furthermore, appropriate fair market valuation by experts is required, including the performance of medical equipment directly linked to treatment results and location conditions. It should be noted that intangible assets such as licenses, long-cultivated medical know-how, and patient trust are difficult to value using the net asset method.

3. Comparable Company Method

The comparable company method calculates the value of a target company by referencing the stock prices or enterprise value multiples (e.g., EV/EBITDA multiples) of publicly traded comparable companies (same industry, similar size). Its advantage is that it allows valuation based on objective market data. However, for medical corporations, there are few publicly traded comparable companies, making direct application of this method often difficult. Therefore, the comparable company method is generally used as a reference value or to supplement other valuation methods.

Advantages of the Comparable Company Method:

• Valuation based on objective market data
• Can be a simple valuation method in some cases

Disadvantages of the Comparable Company Method:

• Difficult to find appropriate comparable companies
• Difficult to reflect the unique business characteristics of medical corporations (non-profit nature, reliance on public medical insurance, etc.)
• Susceptible to fluctuations in market conditions

In practice, even when data from comparable listed companies is scarce, the valuation range is sometimes estimated by applying an EBITDA multiple in a simplified manner, referencing industry reports or multiples from M&A cases published by specialized research firms. Generally, depending on the specialty and scale, an EBITDA multiple of around 2 to 8 times is considered a guideline, but this is merely a reference and can vary significantly depending on the individual circumstances.

Practical Considerations in Medical Corporation Valuation

When valuing medical corporations, it is important to proceed with the following considerations, taking into account the characteristics of each method explained above.

Appropriate Use and Combination of Valuation Methods

Instead of relying on a single valuation method, combining multiple methods for comprehensive judgment leads to a more appropriate business valuation. For example, an approach could involve using the DCF method as the primary method, while using the net asset method to determine the minimum value, and incorporating marketability using the comparable company method (or multiples from comparable M&A cases). Particularly in business succession, the DCF method is often central due to the emphasis on future profitability, but the net asset method is also used concurrently to understand past performance and current asset status.

Valuation Method	Key Focus	Suitable Cases	Considerations for Medical Corporations
DCF Method	Future profitability and growth potential	Potential for growth, potential for synergy effects	Accuracy of forecasts for medical fee revisions, regional medical demand, and medical technology advancements
Net Asset Method	Fair market value of assets and liabilities	Emphasis on asset value, small clinics, understanding liquidation value	Fair market valuation of medical equipment and real estate, difficulty in valuing licenses and know-how
Comparable Company Method	Market valuation levels	Abundant comparable companies and cases for easy comparison	Few comparable medical corporations, divergence from non-profit nature

Specific Issues for Medical Corporations

M&A for medical corporations involves issues different from general corporate M&A, such as the following. These also affect business valuation and must be fully considered.

• Type of Medical Corporation: Profitability, presence of equity stakes (medical corporation associations, foundations, etc.)
• Valuation of Equity Stakes: For medical corporations with equity stakes, the valuation of these stakes is important
• Presence of Funds: For medical corporations with contributed funds, the return of these funds
• Licenses and Notifications: Transferability of various licenses and facility standards
• Medical Fee Receivables: Collectibility of outstanding medical fee receivables
• Medical Equipment and Facilities: Depreciation, maintenance contracts, lease agreements
• Real Estate: Lease agreements, ownership
• Officers and Employees: Employment contracts, retirement benefits
• Off-Balance Sheet Liabilities and Contingent Liabilities: Unpaid overtime, litigation risks, etc.

In particular, for medical corporations with equity stakes, the valuation of these stakes becomes a central issue in negotiations for the transfer price. Furthermore, licenses such as permits for establishing medical facilities and bed permits are essential for the continuity of medical institutions, and the transferability and complexity of procedures for these also affect the valuation.

Receiving Method of Transfer Price and Taxation

The tax treatment varies significantly depending on how the transfer price in M&A is received. The price for the transfer of equity stakes is generally treated as “capital gains” and is subject to separate taxation (20.315% tax rate). This is generally the most advantageous option compared to dividend income or salary income, which are subject to comprehensive taxation (up to 55% tax rate). Receiving it in the form of retirement benefits is also a possibility, but depending on the years of service and amount, the tax burden may be higher than for capital gains. Therefore, when considering an M&A scheme, it is important to collaborate with tax professionals to select the most advantageous method for receiving the transfer price.

Positioning of Business Valuation in the M&A Process

Business valuation is involved from the initial stages of the M&A process. First, there is the “self-assessment” conducted by the seller to understand their company’s value. Next, a “preliminary valuation” is performed at the Letter of Intent (LOI) stage to set a tentative price range. Then, after due diligence (DD) and the disclosure of more detailed information, a “detailed valuation” is typically conducted as the basis for final price negotiations.

During due diligence, financial DD is particularly important. By examining a wide range of items such as the appropriateness of medical fee claims, off-balance sheet liabilities, unpaid overtime, social insurance enrollment status, tax risks, inventory, fixed assets, collectibility of accounts receivable, cash flow, and related party transactions, the accuracy of the valuation is enhanced and potential risks are identified.

Conclusion: Accurate Valuation with Experts

Business valuation for medical corporations requires specialized knowledge and experience due to their unique characteristics. Understanding valuation methods such as the DCF method, net asset method, and comparable company method, and appropriately using them according to the situation while considering the specific issues of medical corporations, leads to the calculation of a fair transfer price. At M&A Medical, experts familiar with the medical industry will conduct an objective and precise business valuation by thoroughly interviewing your corporation’s situation and utilizing multiple valuation methods. Please feel free to contact us for a free consultation when considering M&A. We will propose the optimal solution for your corporation’s smooth business succession and future development.

---

Consult M&A Medical for Medical Succession

M&A Medical is a specialized M&A and business succession support service for medical institutions. As an M&A support institution certified by the Small and Medium Enterprise Agency, we support the successful transfer of clinics and medical corporations struggling with successor shortages, as well as strategic acquisitions, on a success fee basis.

• Initial consultation and preliminary appraisal are free
• No retainer or monthly fees (success fee only)
• Strict confidentiality (proceeding under NDA)
• Service available nationwide for all 47 prefectures and all medical specialties

Please consult us early, even in the initial stages of consideration, whether you “just want to know the market price,” “have no successor,” or “are considering joining a group.”

Apply for Free Consultation